Volume 2.28 | Jul 29

Mammary Cell News 2.28 July 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


TOP STORY

Genetic Risk Score Associated With Breast Cancer Risk; Predictive of Type of Disease  ShareThis
Women with higher risk scores that consisted of having certain genetic variants most strongly linked to breast cancer had an associated higher risk of breast cancer, with these scores also highly predictive of estrogen receptor-positive disease. [Press release from ScienceDaily discussing online prepublication in The Journal of the American Medical Association]

MammaryCytokines_645x110_v01



SCIENCE NEWS

Women in Their 40s Have Lower Mammographic Tumor Detectability, Study Finds
The reduced effectiveness of mammographic screening in women in their forties is primarily due to lower detectability instead of faster tumor growth rate. [Press release from ScienceDaily discussing online prepublication in The Journal of the National Cancer Institute]

OHSU Knight Cancer Institute Researchers Isolate Importance of Gene in Determining How Aggressive a Patient’s Breast Cancer Will Be
Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient’s treatment and enable physicians to provide a more accurate prognosis. [Press release from Oregon Health & Science University discussing online prepublication in Breast Cancer Research and Treatment]

New Molecular Marker Could Predict if Breast Cancer Patients Need Chemotherapy
Scientists working on the study found that the more the marker – called BCL2 – was present in a patient with early stage breast cancer, the more likely they were to survive. [Press release from Cancer Research UK discussing online prepublication in the British Journal of Cancer]

Watch Procedure Now  
Use EpiCult-B® to Culture and Characterize
Human Mammary Epithelial Progenitors

by STEMCELL Technologies
 
 
CLICK HERE TO LEARN MORE STEMCELL Technologies Inc
 




CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Immunoliposomal Delivery of (213)Bi for Alpha-emitter Targeting of Metastatic Breast Cancer
Scientists have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model. [Cancer Res]

ZNF217, a Candidate Breast Cancer Oncogene Amplified at 20q13, Regulates Expression of the ErbB3 Receptor Tyrosine Kinase in Breast Cancer Cells
In this study investigators showed that the ZNF217 transcription factor, amplified at 20q13 in ~20% of breast tumors, regulates ErbB3 expression. [Oncogene]

Changes in Expression of Oestrogen Regulated and Proliferation Genes with Neoadjuvant Treatment Highlight Heterogeneity of Clinical Resistance to the Aromatase Inhibitor, Letrozole
The present study illustrates how changes in the expression of proliferation and oestrogen-regulated genes occurring during neoadjuvant treatment with the aromatase inhibitor, letrozole, may define distinctive tumour subgroups and suggest different mechanisms of resistance in clinically endocrine resistant breast cancers. [Breast Cancer Res]

MYB Suppresses Differentiation and Apoptosis of Human Breast Cancer Cells
The data implies that MYB function is critical in regulating the balance between proliferation, differentiation, and apoptosis in mammary epithelial cells. Moreover, their findings suggest MYB may be a viable therapeutic target in breast cancer and suggest specific approaches for exploiting this possibility. [Breast Cancer Res]

GRB7 Protein Over-Expression and Clinical Outcome in Breast Cancer
The purpose of this study was to examine the clinical significance of the growth factor receptor-bound protein-7 (GRB7) protein expression in human breast cancer. [Breast Cancer Res Treat]

The CASP8 rs3834129 Polymorphism and Breast Cancer Risk in BRCA1 Mutation Carriers
Researchers tested the effect of the rs3834129 del allele on breast cancer risk in BRCA mutation carriers. [Breast Cancer Res Treat]

Integrated miRNA and mRNA Expression Profiling of the Inflammatory Breast Cancer Subtype
In this study, scientists explored whether altered miRNA expression has a prominent role in defining the inflammatory breast cancer phenotype. [Br J Cancer]

CLINICAL RESEARCH

Incidence of Breast Cancer and Its Subtypes in Relation to Individual and Multiple Low-Penetrance Genetic Susceptibility Loci
The objective of this study was to analyze breast cancer risk, overall and by tumor subtype, in relation to 14 individual single-nucleotide polymorphisms previously linked to the disease, and in relation to a polygenic risk score. [JAMA]

A Simulation Model Investigating the Impact of Tumor Volume Doubling Time and Mammographic Tumor Detectability on Screening Outcomes in Women Aged 40-49 Years
The age-specific differences in mammographic tumor detection contribute more than age-specific differences in tumor growth rates to the lowered performance of mammography screening in younger women. [J Natl Cancer]

Breast Carcinoma with Amplified HER2: a Gene Expression Signature Specific for Trastuzumab Resistance and Poor Prognosis
In an effort to clarify and optimize the treatment regimens for breast cancer patients who are candidates to receive trastuzumab, investigators sought to analyze whether a distinctive genetic signature could be characterized that would reliably predict the treatment outcome. [Mod Pathol]

BCL2 in Breast Cancer: a Favourable Prognostic Marker Across Molecular Subtypes and Independent of Adjuvant Therapy Received
This study establishes the rationale for introduction of B-cell lymphoma 2 (BCL2) immunohistochemistry to improve prognostic stratification. [Br J Cancer]


Increased Mortality in HER2 Positive, Oestrogen Receptor Positive Invasive Breast Cancer: a Population-Based Study
This study assessed the impact of human epidermal growth factor receptor 2 (HER2) status on the outcomes in an unselected population of breast cancer patients who did not receive HER2-targeted therapy. [Br J Cancer]




INDUSTRY NEWS

Cytori Gains Stem Cell Device Approval in Europe for Breast Cancer Reconstruction and Soft Tissue Repair
Cytori Therapeutics received expanded European approval for its Celution(R) System, a medical device that extracts and separates stem and regenerative cells from a patient’s own fat tissue. [Cytori Therapeutics Press Release]

ABRAXANE(R) Approved For Marketing In Japan For Breast Cancer
Taiho Pharmaceutical Co., Ltd., announced that it has received approval to manufacture and market Abraxane® I.V. Infusion 100 mg in Japan, an antineoplastic for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound). [Taiho Pharmaceutical Co., Ltd. Press Release]

Axela Acquires Xceed Molecular Creating Powerhouse in Robust and Easy-to-Use Systems for Translational Medicine
Axela Inc. has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. [Axela Inc. Press Release]

Dako and Omnyx Sign Agreement within Digital Pathology
Dako Denmark A/S and Omnyx, LLC announced that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results. [Dako Denmark A/S Press Release]

Merrimack Pharmaceuticals and Sanofi-Aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and Exemestane in Breast Cancer
Merrimack Pharmaceuticals, Inc. and Sanofi-Aventis Ltd. announced that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients. [Merrimack Pharmaceuticals Inc. Press Release]

The Marilyn B. Gula Mountains of Hope Foundation Donates Additional Research Funds to University Hospitals Ireland Cancer Center and TGen
The Marilyn B. Gula Mountains of Hope Foundation continues its fight against advanced breast cancer with an additional $60,000 donation to University Hospitals Ireland Cancer Center, bringing the total donated to $110,000 during the past year. In addition, the Mountains of Hope Foundation donated $50,000 to the Translational Genomics Research Institute based in Phoenix for a total contribution of $300,000 within the past two years. [The Marilyn B. Gula Mountains of Hope Foundation Press Release]

Two UC San Diego Researchers Awarded $780,000 in Grants from Susan G. Komen for The Cure®
Researchers at the University of California (UC), San Diego School of Medicine received nearly $780,000 from the Susan G. Komen for the Cure® for two studies regarding estrogen levels and the behavior of breast cancer tumors. [University of California, San Diego Press Release]

Susan G. Komen Awards Case Western Reserve School of Medicine Nearly $500,000 to Lead a Clinical Study Aimed to Improve Outcomes for Older Women with Breast Cancer
Cynthia Owusu, MD, associate professor at Case Western Reserve University and geriatric-oncologist at University Hospitals Case Medical Center, received nearly $500,000 from Susan G. Komen For the Cure to fund a novel three-year study aimed at improving outcomes for older women with newly-diagnosed breast cancer. [Case Western Reserve School of Medicine Press Release]




POLICY NEWS

CIHR Team Grant to Fund Wide-Ranging Research into Physical Activity and Breast Cancer Survivorship
Over the next five years, a diverse, multi-disciplinary team of researchers led by Dr. Kerry Courneya of the University of Alberta and Dr. Christine Friedenreich of Alberta Health Services will conduct a series of five large research projects to probe the impacts of physical activity on breast cancer thanks to a $2.5 million team grant over five years from the Canadian Institutes of Health Research (CIHR). [University of Alberta, Canada]

Brussels to Invest $8.3 Billion in Research
Research organizations, universities, and industry will receive a sum of 6.4 billion euros next year in the European Commission’s largest ever allocation for research and innovation. [European Commission, European Union]

Consumer Gene Test Results Misleading – U.S. Probe
People who send off their saliva to genetic testing companies to find out their risk for prostate cancer or diabetes are likely to get different results, depending on the company they choose, government investigators told lawmakers. [Government Accountability Office, United States]

Gene-Testing Companies May Need U.S. Regulators Review, FDA Letters Say
The U.S. Food and Drug Administration sent letters to gene-testing companies saying the tests “appear to meet the definition of a device.” [Federal and Drug Administration, United States]

NIH Asks for Input on Closing Loophole in Conflict-of-Interest Rule
Responding to yet another flap about the influence of drug companies on biomedical research, the National Institutes of Health (NIH) has decided it needs more time to revise its rules for policing conflicts of interest so that sanctions will move with an investigator if he or she changes institutions. [National Institutes of Health, United States]
 
Center for Scientific Review; Notice of Closed Meeting (Doc. 2010-18052) [National Institutes of Health, United States]

Instrument Development for Biomedical Applications (R21) (RFA-RR-10-009) [National Institutes of Health, United States]

Biosafety in Microbiological and Biomedical Laboratories (BMBL): 5th Edition (NOT-OD-10-117)  [National Institutes of Health, United States]

Bioengineering Research Partnerships (BRP)[R01] (PAR-10-234) [National Institutes of Health, United States]

National Institute of Biomedical Imaging and Bioengineering Program Project (P01) Applications (PAR-10-233)  [National Institutes of Health, United States]

Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors [Docket Number NIH-2010-0001][Department of Health and Human Services, United States]



EVENTS (Listed by Date)

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore City, Singapore

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

2010 Breast Cancer Symposium
October 1-3, 2010
Washington, DC, United States

2nd International Inflammatory Breast Cancer Conference
October 6-7, 2010
Marseille, France

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

16th World Congress of the International Society of Senology
October 20-22, 2010
Valencia, Spain

The 2010 American Institute for Cancer Research (AICR) Annual Research Conference on Food, Nutrition, Physical Activity & Cancer
October 21-22, 2010
Washington, DC, United States

NEW MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

NEW UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States



JOB OPPORTUNITIES

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Have we missed an important article or publication in Mammary Cell News? Click here to submit!



Comments or Suggestions? Email [email protected] with your feedback.


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us